Loading…
← CockpitCompetitor Analysis › NVCT Nuvectis Pharma, Inc.Open in the cockpit ↗

Nuvectis Pharma, Inc.NVCTCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum leader 91
Mkt cap
$698M
US dollars, full cap
Free float
65%
of shares outstanding
$/day
$4.17M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
111 days
9 Mar 2027
Close · USD$20.29
1D+5.7%
1W-3.4%
1M-1.5%
3M-13.1%
6M+90.9%
YTD+168.7%
1Y+233.7%
ATR %7.4%
Beta0.76
52w lowhigh30.7% off high

What Nuvectis Pharma does

Employees: 13

Nuvectis Pharma at a glance

Size Nuvectis Pharma (NVCT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $698M, the 2459th largest of 3,085 United States companies the cockpit tracks. Shares closed at $20.29 on 18 Nov 2026.

Performance Over six months the shares gained 90.9%, against -10.1% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).

Relative performance

10020021 May 202621 Aug 202618 Nov 2026NVCT 185Peer median 92
Six months, rebased to 100: Nuvectis Pharma against the median of its 20 peers (local-currency closes).

Nuvectis Pharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit$0$0$0$0$0
EBITDA-$52.1M-$27.6M-$19.8M-$22.9M-$19.2M
Net income-$50.5M-$28.9M-$19.0M-$22.3M-$19.1M
Free cash flow-$40.3M-$16.0M-$12.2M-$16.0M-$13.6M
Capital expenditure$0$0$0$0$0
Total debt$0$0$0$0$0

Quarterly statements and history in the cockpit →

Nuvectis Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%-10%0%+10%600829498500091545340570600351SGMT688658688488ANNX6005306885662186300705FDC600479NVCT6-month return →1-month return →
Up and to the right = strong over both horizons. Nuvectis Pharma is the large dot.

Nuvectis Pharma competitors and peer comparison

How Nuvectis Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nuvectis Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureNVCTPeer medianRank in peer set
1-month return-1.5%-5.6%8th highest of 21
6-month return+90.9%-10.1%highest of 21
Distance from 52-week high-30.7%-34.0%9th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%0.6×4.0%+5.3%
Earth 4985.TJapan$687M+7%+4%4%0.5×-1.6%-1.8%
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%2.5×n/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%0.8×n/an/a
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%0.3×n/an/a
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%1.6×-8.3%-2.8%
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%2.6×-4.8%+6.4%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%1.7×n/an/a
Philogen PHIL.MIItaly$672M-11%+295%79%0.9×n/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%6.7×31.9%+19.8%
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%3.9×n/an/a
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%16.1×42.7%-0.9%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%3.8×5.9%+11.3%
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%1.1×-11.8%+1.9%
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%2.5×n/an/a
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%1.8×-2.0%+26.1%
FDC FDC.NSIndia$653M+3%+10%14%2.4×25.2%+10.3%
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%1.4×-2.1%0.0%

Questions

Which companies are Nuvectis Pharma's closest peers?
The cockpit's peer set: HPGC Renmintongtai Pharmaceutical (600829.SS), Earth (4985.T), Shandong Wit Dyne Health (000915.SZ), Mochida Pharmaceutical (4534.T), China Traditional Chinese Medicine (0570.HK), Yabao Pharmaceutical (600351.SS), Hunan Fangsheng Pharmaceutical (603998.SS), Sagimet Biosciences (SGMT).
How has Nuvectis Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +90.9% against -10.1% for the median peer; over one year +233.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.